By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – UK phosphoproteomics firm Activiomics today announced it has received a £500,000 ($806,715) investment, which it will use to further build partnerships with pharmaceutical and biotech firms and to identify novel biomarkers.

Leading the round was IP Group. Additional investors included IP Venture Fund and members of Activiomics' management.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A European team has launched a four-year study to develop a test to gauge cervical, ovarian, uterine, or aggressive breast cancer risk in women.

As interest in personalized medicine grows, government contractors are entering the field, the Washington Post reports.

In PNAS this week: spatiotemporal study of lncRNA expression, role of extrachromosomal, circular DNAs in yeast, and more.

In PLOS this week: Plasmodium knowlesi population genetics, oral microbiome of infants and children, and more.